AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2025
Jan 8, 2025
31071_dirs_2025-01-07_c597ef9f-8165-4fa9-a1d6-c844a75233f7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2025-01-04
Reporting Person: Hamilton James C (Chief Discovery/Trans Medicine)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-04 | Common Stock | A | 100000 | — | Acquired | 304851 | Direct |
| 2025-01-06 | Common Stock | S | 21758 | $19.68 | Disposed | 283093 | Direct |
| 2025-01-06 | Common Stock | S | 10971 | $20.11 | Disposed | 272122 | Direct |
Footnotes
F1: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments.
F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Partial disposition of RSUs to satisfy tax withholding obligations.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.